Moderate-Affinity Affibodies Modulate the Delivery and Bioactivity of Bone Morphogenetic Protein-2

Jonathan Dorogin1, Henry B Hochstatter1,2, Samantha O Shepherd3

  • 1Department of Bioengineering, Knight Campus for Accelerating Scientific Impact, University of Oregon, 6231 University of Oregon, Eugene, OR, 97403, USA.

PubMed
Summary

Researchers developed novel affibodies to control bone morphogenetic protein-2 (BMP-2) release. These protein binders, when conjugated to hydrogels, effectively modulate BMP-2 delivery and activity for potential clinical use.